Targeting memory loss with aspirin, a molecular mechanism perspective for future therapeutic approaches

被引:0
|
作者
Masoumeh Gholami
Mehdi Sadegh
Masoumeh Koroush-arami
Shaghayegh Norouzi
Rasoul Jafari Arismani
Erfan Asadi
Mohammad Amini
Nahid Khodayari
机构
[1] Arak University of Medical Sciences,Department of Physiology, Faculty of Medicine
[2] Iran University of Medical Sciences,Department of Neuroscience, School of Advanced Technologies in Medicine
[3] University of Kentucky,Markey Cancer Center
[4] Arak University of Medical Sciences,Department of Urologic Surgery, Faculty of Medicine
[5] Arak University of Medical Sciences,Medical Student, Faculty of Medicine
来源
Inflammopharmacology | 2023年 / 31卷
关键词
Acetylsalicylic acid; Cyclooxygenase; Dementia; Alzheimer; Synaptic plasticity;
D O I
暂无
中图分类号
学科分类号
摘要
Acetylsalicylic acid (ASA), also known as aspirin, was discovered in 1897 as an acetylated form of salicylate. It has been widely used for its anti-inflammatory and antiplatelet effects. It is commonly used for its cardiovascular benefits and is prescribed as secondary prophylaxis after a heart attack. Furthermore, low-dose, long-term ASA is used to reduce the risk of heart attack and stroke in individuals without prior cardiovascular disease. Acetylsalicylic acid acts as a non-selective inhibitor of cyclooxygenase (COX), which inhibits the synthesis of prostaglandins and prevents pro-inflammatory cytokines. Findings suggest that targeting cytokines and growth factors could be a potential therapeutic strategy for reducing neuroinflammation and slowing down the progression of dementia. Additionally, prostaglandins contribute to synaptic plasticity and can act as retrograde messengers in synapses. Research has implicated COX-1, one of the isoforms of the enzyme, in neuroinflammation and neurodegenerative disorders. The inhibition of COX-1 might potentially prevent impairments in working memory and reduce neuroinflammation caused by beta-amyloid proteins in some conditions, such as Alzheimer’s disease (AD). Cyclooxygenase-2, an inducible form of the enzyme, is expressed in cortical and hippocampal neurons and is associated with long-term synaptic plasticity. The inhibition or knockout of COX-2 has been shown to decrease long-term potentiation, a process involved in memory formation. Studies have also demonstrated that the administration of COX-2 inhibitors impairs cognitive function and memory acquisition and recall in animal models. There remains a debate regarding the effects of aspirin on dementia and cognitive decline. Although some studies suggest a possible protective effect of non-steroidal anti-inflammatory drugs, including aspirin, against the development of AD, others have shown inconsistent evidence. This review provides an overview of the effects of ASA or its active metabolite salicylate on learning, memory, and synaptic plasticity.
引用
收藏
页码:2827 / 2842
页数:15
相关论文
共 50 条
  • [21] A Narrative Review of Diabetic Macroangiopathy: From Molecular Mechanism to Therapeutic Approaches
    Jiacheng Yin
    Xiaoxu Fu
    Yue Luo
    Yuling Leng
    Lianjun Ao
    Chunguang Xie
    Diabetes Therapy, 2024, 15 : 585 - 609
  • [22] Recent advancements in the therapeutic approaches for Alzheimer's disease treatment: current and future perspective
    Sharma, Amit
    Rudrawar, Santosh
    Bharate, Sandip B.
    Jadhav, Hemant R.
    RSC MEDICINAL CHEMISTRY, 2025, 16 (02): : 652 - 693
  • [23] Targeting transthyretin - Mechanism-based treatment approaches and future perspectives in hereditary amyloidosis
    Dohrn, Maike F.
    Ihne, Sandra
    Hegenbart, Ute
    Medina, Jessica
    Zuchner, Stephan L.
    Coelho, Teresa
    Hahn, Katrin
    JOURNAL OF NEUROCHEMISTRY, 2021, 156 (06) : 802 - 818
  • [24] Therapeutic approaches targeting molecular signaling pathways common to diabetes, lung diseases and cancer
    Raguraman, Rajeswari
    Srivastava, Akhil
    Munshi, Anupama
    Ramesh, Rajagopal
    ADVANCED DRUG DELIVERY REVIEWS, 2021, 178
  • [25] Nanomedicine-driven molecular targeting, drug delivery, and therapeutic approaches to cancer chemoresistance
    Khot, Vishwajeet M.
    Salunkhe, Ashwini B.
    Pricl, Sabrina
    Bauer, Joanna
    Thorat, Nanasaheb D.
    Townley, Helen
    DRUG DISCOVERY TODAY, 2020, 26 (03) : 724 - 739
  • [26] Molecular mechanism and therapeutic targeting of necrosis, apoptosis, pyroptosis, and autophagy in cardiovascular disease
    Li, Pan
    Dong, Xiao-Rong
    Zhang, Bei
    Zhang, Xin-Tong
    Liu, Jing-Zhuo
    Ma, De-Sheng
    Ma, Li
    CHINESE MEDICAL JOURNAL, 2021, 134 (22) : 2647 - 2655
  • [27] Molecular mechanism and therapeutic targeting of necrosis, apoptosis, pyroptosis, and autophagy in cardiovascular disease
    Pan Li
    Xiao-Rong Dong
    Bei Zhang
    Xin-Tong Zhang
    Jing-Zhuo Liu
    De-Sheng Ma
    Li Ma
    中华医学杂志英文版, 2021, 134 (22) : 2647 - 2655
  • [28] Targeting IAP proteins in cancer: From molecular mechanism to therapeutic application.
    Fulda, Simone
    CANCER RESEARCH, 2013, 73 (08)
  • [29] Molecular mechanism of ageing and therapeutic advances through targeting glycative and oxidative stress
    Tkemaladze, Jaba
    FRONTIERS IN PHARMACOLOGY, 2024, 14
  • [30] Targeting GM2 Ganglioside Accumulation in Dementia: Current Therapeutic Approaches and Future Directions
    Kumar, Sanjesh
    Panda, Siva Prasad
    CURRENT MOLECULAR MEDICINE, 2024, 24 (11) : 1329 - 1345